

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

application of:

Appl. No.: 10/559,823

Filed: December 2, 2005

For: ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED

COMPOUNDS

Art Unit: To be assigned

Confirmation No. To be assigned

Examiner: To be assigned

Atty. Docket: 02351.0005.PCUS00

## **Information Disclosure Statement**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is

further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
  - □ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under \$1.53(d);
  - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
  - c. Before the mailing date of a first Office Action on the merits;
  - □ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
  - □ a. I hereby state that each item of information contained in this Information Disclosure

    Statement was first cited in any communication from a foreign patent office
    in a counterpart foreign application not more than three months prior to the
    filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
  - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
  - □ c. Attached is our Check in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. § 1.17(p).

□ 3.	This Information Disclosure Statement is being filed more than three months after the U.S.								
	filing date and after the mailing date of a Final Rejection or Notice of Allowance, but								
		on or before payment of the Issue Fee. The U.S. Patent and Trademark Office is							
		hereby authorized to charge \$, to our Deposit Account No. 08-3038							
		referencing docket numberin payment of the fee under 37							
		C.F.R. § 1.17(p), and							
	□ a.	I hereby state that each item of information contained in this Information Disclosure							
		Statement was first cited in any communication from a foreign patent office							
		in a counterpart foreign application not more than three months prior to the							
		filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or							
	□ b.	I hereby state that no item of information in this Information Disclosure Statement							
		was cited in a communication from a foreign patent office in a counterpart							
		foreign application, and, to my knowledge after making reasonable inquiry,							
		no item of information contained in this Information Disclosure Statement							
		was known to any individual designated in 37 C.F.R. § 1.56(c) more than							
		three months prior to the filing of this Information Disclosure Statement. 37							
		C.F.R. § 1.97(e)(2).							
□ 4.	Relev	ance of the non-English language document(s) is discussed in the present specification.							
<b>□</b> 5.	The document(s) was/were cited in a corresponding foreign application. An English								
		language version of the foreign search report is attached for the Examiner's							
		information.							
<b>□</b> 6.	A cor	acise explanation of the relevance of the non-English language document(s) appears							
		below:							
<b>1</b> 7.	The E	xaminer's attention is directed to co-pending U.S. Patent Application No.							
		filed, which is directed to related technical subject matter. The							
		identification of this U.S. Patent Application is not to be construed as a waiver of							
		secrecy as to that application now or upon issuance of the present application as a							
	,	patent. The Examiner is respectfully requested to consider the cited application and							
		the art cited therein during examination.							

Attorney Docket No.02351.0005.PCUS00 Appl. No. 10/559,823

$\square$ 8. Copies of the documents were cited by or submitted to the Office in Appli	cation No.												
, filed, which is relied upon for an earlier filing dat	e under 35												
U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).													
It is respectfully requested that the Examiner initial and return a copy of the enclosed													
PTO-1449, and to indicate in the official file wrapper of this patent application that the documents													
have been considered.													
The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or													
credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number													
02351.0005.PCUS00.													
Respectfully submitted,													
Date: April 26, 2006  Viola T. Kung (Reg. No. 4(131)													

HOWREY LLP

2941 Fairview Park Drive Box 7

Falls Church, VA 22042 Tel: (650) 798-3570 Fax: (650) 798-3600

SERIAL NO.

INFORMATION DISCLOSURE CITATION PTO-1449				ATTY. DOCKET NO. 02351.0005. PCUS00			SERIAL NO. 10/559,823			
				APPLICANT : TUNG, Jay S.						
		FILING DATE : 12/02/2005			GROUP					
		U	.S. P	ATENT DOCUMENTS						
EX'R INITIAL	PATENT NO. DATE		_			ASS	SUBCLASS	FILING DAT		
/G.S./	6,153,652	11-20	000	Wu, et al.						
1	6,191,166	02-20	001	AUDIA et al.						
1	6,211,235	04-20	001	Wu, et al.						
_	US 6,207,710 B1	03-20	001	AUDIA et al.						
V	US 2006-0052426	03-2006		Despeyroux, et al.						
•										
		T		PATENT DOCUMENT	$\neg$					
EX'R INITIAL	PATENT NO.	DATE MM-YYYY		COUNTRY	CLASS		SUBCLASS	YES	NO	
/G.S./	WO 99/66934	12-1	999	PCT						
	WO 00/38618	07-2	000	PCT						
	WO 00/77030	12-2	000	PCT						
V										
	OTHER DOCUM	MENTS (I	nclud	ing Author, Title, Date,	Pertir	ent P	ages, Etc.)			
EX'R INITIAL	DOCUMENT									
EXAMINE	: /Golam Shameem	/		DATE CO	NSID	ERED	02/04/20	10		
the citation applicant.	if not in conformance a	nd not co	nside	or not the citation conform red. Include a copy of thi	s form	with I	next communic	ation to		
cited by or	sk is placed beside the submitted to the PTO in ınder 35 U.S.C. §120. 37	a prior ap	plicat	er, a copy is not provided ion that is identical in the ).	staten	use the nent a	reference was nd relied upon	s previo for an e	usly earlier	

ATTY. DOCKET NO.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.S./